DPYD and pancreatic neoplasm: Wogonin may enhance the sensitivity of gemcitabine in pancreatic cancer by inhibiting AKT2, CCL2, HSP90AA1, PDE5A, or activating PTGS1, BCHE, SERPINB5, CA2, SRC, DGKA, HIF1A, PTGS2, ABCA1, DPYD and AKR1C3 (Figure 3A).